Financial Statements — FUSE
Balance Sheet
(in millions USD)| Metric | Q2
2026 | Q1
2026 | Q3
2025 |
|---|
| Cash & Equivalents | 0.37 | 1.77 | -- |
| Short-term Investments | -- | -- | 12.29 |
| Accounts Receivable | 1.13 | 1.24 | -- |
| Total Current Assets | 1.99 | 3.74 | 12.35 |
| Property, Plant & Equipment | 0.27 | 0.29 | -- |
| Intangible Assets | 0.23 | 0.21 | -- |
| Total Non-current Assets* | 0.50 | 0.50 | 0.00 |
| Total Assets | 3.17 | 4.94 | 12.35 |
| Accounts Payable | 4.97 | 4.68 | 0.35 |
| Short-term Debt | 0.12 | 0.17 | -- |
| Total Current Liabilities | 18.74 | 18.13 | 43.91 |
| Long-term Debt | 0.30 | 0.30 | -- |
| Total Non-current Liabilities* | 1.79 | 1.85 | 0.00 |
| Total Liabilities | 20.53 | 19.98 | 43.91 |
| Retained Earnings | (38.95) | (36.10) | (32.88) |
| Total Stockholder Equity | (17.35) | (15.03) | (11.60) |
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2
2026 | Q1
2026 | Q4
2025 | Q3
2025 |
|---|
| Total Revenue | 1.79 | 1.88 | -- | -- |
| Cost of Revenue | 0.83 | 0.93 | -- | -- |
| Gross Profit | 0.96 | 0.95 | -- | -- |
| Research & Development | 0.29 | 0.30 | -- | -- |
| Selling, General & Admin | 2.98 | 3.27 | 8.09 | 0.03 |
| Total Operating Expenses | 3.65 | 3.98 | 8.35 | 1.13 |
| Operating Income | (2.69) | (3.03) | (4.04) | (1.13) |
| Pretax Income | (2.85) | (0.87) | -- | -- |
| Tax Provision | 0.00 | 0.00 | -- | -- |
| Net Income | (2.85) | (0.87) | 21.18 | (19.84) |
| Basic EPS | (0.10) | (0.03) | -- | -- |
| Diluted EPS | (0.10) | (0.03) | -- | -- |
Cash Flow Statement
(in millions USD)| Metric | Q2
2026 | Q1
2026 | Q4
2025 | Q3
2025 |
|---|
| Operating Cash Flow | (1.29) | (2.22) | (5.29) | (0.24) |
| Capital Expenditures | 0.01 | 0.02 | -- | -- |
| Free Cash Flow* | (1.29) | (2.24) | -- | -- |
| Investing Cash Flow | (0.06) | (0.06) | (3.91) | 3.74 |
| Financing Cash Flow | (0.05) | (0.17) | 13.00 | (3.58) |
* Derived from reported values
